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spatial Quantitation of 
Drugs in tissues using Liquid 
extraction surface Analysis Mass 
spectrometry Imaging
John G. swales1,2, Nicole strittmatter1, James W. tucker1, Malcolm R. Clench2, 
peter J. H. Webborn1 & Richard J. A. Goodwin1
Liquid extraction surface analysis mass spectrometry imaging (LesA-MsI) has been shown to be an 
efective tissue proiling and imaging technique, producing robust and reliable qualitative distribution 
images of an analyte or analytes in tissue sections. Here, we expand the use of LesA-MsI beyond 
qualitative analysis to a quantitative analytical technique by employing a mimetic tissue model 
previously shown to be applicable for MALDI-MSI quantitation. Liver homogenate was used to generate 
a viable and molecularly relevant control matrix for spiked drug standards which can be frozen, 
sectioned and subsequently analyzed for the generation of calibration curves to quantify unknown 
tissue section samples. The efects of extraction solvent composition, tissue thickness and solvent/
tissue contact time were explored prior to any quantitative studies in order to optimize the LESA-MSI 
method across several diferent chemical entities. The use of a internal standard to normalize regional 
diferences in ionization response across tissue sections was also investigated. Data are presented 
comparing quantitative results generated by LESA-MSI to LC-MS/MS. Subsequent analysis of adjacent 
tissue sections using DesI-MsI is also reported.
A drugs distribution and the relationship with eicacy and safety are important considerations during drug devel-
opment. It is crucial that a compound is present in suicient quantity at the site of action to deliver eicacy. 
Equally, excessive abundance of the drug in tissues may lead to unwanted toxicological indings rendering the 
drug unsafe.
Drug distribution has historically been assessed in various ways. Tissue homogenization techniques, coupled 
to liquid chromatography and mass spectrometry have been the mainstay to quantify drugs in tissues1. However, 
this approach results in the loss of all spatial information from the sample and merely provides an average concen-
tration within the tissue. here is also a risk of variation caused by residual blood contamination.
Mapping and quantifying the distribution of compounds in vivo was historically performed using radiolabeled 
compounds in techniques such as quantitative whole body autoradiography (QWBA)2,3. he technique is reliable, 
sensitive, quantitative and retains meaningful spatial information. However, the necessity for a radiolabeled com-
pound is a major drawback that can lead to signiicant ‘synthesis’ delays. Furthermore, quantitation of the parent 
drug can be misrepresented due to drug metabolites that still include the radiolabel.
Mass spectrometry imaging (MSI) is a complementary, viable, multiplex and label free way of elucidating 
the distribution of drugs and endogenous metabolites directly from the surface of tissue sections4. MSI is a term 
used to describe a group of complementary surface sampling technologies based on diferent mass spectrometry 
ionization methods. he most commonly used are matrix assisted laser desorption ionization (MALDI-MSI)5–7, 
secondary ion mass spectrometry (SIMS-MSI)8, desorption electrospray ionization (DESI-MSI)9,10 and nano-
electrospray ionization based liquid microjunction techniques such as liquid extraction surface analysis 
(LESA-MSI)11,12. Each technique has innate advantages and disadvantages in sensitivity, speed and spatial 
resolution.
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MALDI-MSI and more recently DESI-MSI have been gaining popularity within the pharmaceutical indus-
try as scientiically and economically feasible technology platforms to assess drug distribution. MALDI-MSI is 
capable of delivering images at low micron spatial resolution13, a drawback however is that it is not easily appli-
cable to all analytes oten requiring lengthy matrix optimization or on-tissue chemical derivatization to ensure 
detection14. DESI-MSI is an electrospray ionization based technique and thus has a much wider chemical scope. 
Spatial resolution is more limited than MALDI-MSI, typically around 50–100 µ m. SIMS-MSI is again limited 
in chemical scope, high energy ionization and the technique being combined with low spectral resolution mass 
analyzers make it unsuitable for the analysis of medium and high size molecules. SIMS-MSI is capable of nanom-
eter spatial resolution, however the technique has not been widely adopted within the pharmaceutical industry, 
primarily due to high set up costs and the availability of the technique within academia as a fee for service answer 
to bespoke distribution questions. LESA-MSI is a surface sampling technique that has been shown to be widely 
applicable and sensitive but can deliver only low spatial resolution images (typically 1000 µ m)11. he technique 
can be combined with Orbitrap or time of light mass spectrometers for efective use as a proiling tool15 but has 
also been used efectively with high sensitivity triple quadrupole mass spectrometers operated in selected reaction 
monitoring mode for mass spectrometry imaging16.
All of the above techniques provide relatively fast and reliable qualitative localization information that can 
be used to show drug distribution to target tissues or drug accumulation in tissues where a toxic efect has been 
observed. However this data is of a qualitative nature only and as such is oten hard to put into context and dif-
icult to draw meaningful conclusions from without a quantitative determination of the drug levels within the 
tissues. Quantitative MSI methods for drugs have been widely reported, most prevalently for MALDI-MSI17. 
Groseclose and Castellino published a report based on the use of tissue mimetics for the quantitation of drug 
compounds in liver tissue sections using MALDI-MSI18. Likewise, Nilsson et al. published MALDI-MSI data 
showing the quantitation of tiotropium in rat lung tissue utilizing calibration standard spotting on control 
tissue19. Other reported techniques employ the use of internal standards to normalize diferences in ionization 
eiciency across tissue sections20,21. Quantitative methods have also been published for nano-DESI-MSI22 based 
on similar techniques as those employed in MALDI-MSI.
he research presented here details a quantitative LESA-MSI method using tissue mimetics for the quantita-
tion of various drugs in tissue sections. Details of method optimization are reported. he quantitative LESA-MSI 
method was directly compared to results obtained by traditional LC-MS/MS tissue homogenization analysis and 
to results generated by DESI-MSI analysis.
Methods
Materials and reagents. Analytical grade acetonitrile, methanol and formic acid were obtained from Fisher 
Scientiic (Loughborough, Leicestershire, UK). 2-methylbutane was obtained from Sigma-Aldrich (Poole, Dorset, 
UK). Test compounds were obtained in house from AstraZeneca compound management group (Macclesield, 
Cheshire, UK) with the exception of moxiloxacin and SCH-23390 which were purchased from Sigma-Aldrich 
(Poole, Dorset, UK) and clozapine-d4 which was purchased from Qmx Laboratories (haxted, Essex, UK).
Animals. Adult male Hans Wistar rats (approximate weight 260 g) were obtained from Charles River 
Laboratories (Margate, Kent, UK) and were acclimatized on site for a minimum of 3 days prior to dosing. 
Compounds were administered by oral gavage and were formulated in 5% dimethylsulfoxide/95% (30% w/v 
Captisol in water). Control animals were dosed with vehicle via the same administration route.
The study was performed under project license 40/3484, procedure number 10 and was reviewed and 
approved by the Institutional Animal Welfare and Ethical Review Body within AstraZeneca and was conducted in 
accordance with the animal care and ethics described in “Guidance on the Operations of the Animals (Scientiic 
Procedures) Act 1986” issued by the UK Home Oice.
Dosing and scheduling. Liver samples were taken from 1 animal dosed with vehicle, 2 animals dosed dis-
cretely with olanzapine (10 mg/kg), and 2 cassette dosed animals (Moxiloxacin, olanzapine, erlotinib and terfen-
adine at 25, 10, 10 and 25 mg/kg respectively). Animals were euthanized at either 2 or 6 hrs post dose.
All tissue dissection was performed by trained AstraZeneca staf. Liver samples were harvested at termination 
and snap-frozen in 2-methylbutane on dry-ice, subsequent transfer of tissues was done on dry-ice and samples 
were stored at − 80 °C until tissue processing.
tissue processing. Tissue sections were cryosectioned at a thickness of 14 µ m and thaw mounted onto 
indium tin oxide (ITO) coated MALDI target slides (Bruker Daltonics, Bremen, Germany) for LESA analysis 
(ITO slides are not essential for LESA analysis but are used as standard within our laboratories to allow sections to 
be analyzed by either LESA or MALDI) and Superfrost slides (Fisher Scientiic) for DESI analysis. Sections were 
taken at approximately equal depth from all samples. Mimetic calibration standards were thaw mounted onto the 
slide prior to the dosed unknowns in a semi random order to mitigate the risk of bias caused by duration on slide 
(mounting order - blank, 1, 20, 0.1, 5, 50, 0.5, 10, 100 nmol/g). Tissue sections from dosed and control animals 
were randomly thaw-mounted on the same slides (order cassette 2 h, discrete 2 h, control, cassette 6 h, discrete 
6 h). Mounted tissue sections, were stored at − 80 °C until analysis.
Preparation of liver mimetics. Liver mimetics were prepared by homogenizing control liver tissue using a 
Fisher Powergen 500 homogenizer for a minimum of 30 s at room temperature. Each 250 µ L of liver homogenate 
was pipetted into 9 separate molds (prepared from the bottom end of a 2 mL plastic Pasteur pipette bulb) and sub-
sequently weighed. Appropriate volumes of compound solution (containing olanzapine, moxiloxacin, erlotinib 
and terfenadine) were spiked into the homogenate (assuming 1 mL of standard equivalent to 1 g of tissue and 
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not accounting for density diferences) to form liver homogenate calibration standards at 0, 0.1, 0.5, 1, 5, 10, 20, 
50 and 100 nmol/g. he homogenates were then frozen at − 80 °C for a minimum of 1 h prior to cryosectioning.
LESA Optimization experiments. Extraction solvent composition. hree solvents were used (acetonitrile 
(ACN), methanol (MeOH) and isopropyl alcohol (IPA)) at 4 diferent compositions in water (solvent content 
50, 60, 70 and 80%), each extraction solvent contained 0.1% formic acid to promote positive ionization and aide 
conductivity in the nanospray interface. Mimetic liver tissue containing four analytes (clozapine, albendazole, 
tamoxifen and astemizole) spiked at a concentration of 50 nmol/g and covering a LogD (pH 7.4) range between 
2.9 and 4.09 was sectioned at a thickness of 14 µ m and subsequently thaw mounted onto microscope slides. Ten 
LESA extractions were performed at random points across the tissue with mean signal intensity used to compare 
the diferent solvents and solvent compositions.
Tissue thickness. he efect of tissue thickness was assessed using mimetic liver tissue spiked with clozapine, 
albendazole, tamoxifen and astemizole at a concentration of 50 nmol/g and sectioned at 12, 25 and 50 µ m thickness. 
Ten extractions were performed at random points across the tissue with mean signal intensity used to compare 
the diferences between the sections.
Solvent dwell time. he efects of solvent dwell time on signal intensity were explored using mimetic liver tissue 
sections cut at 12, 25 and 50 µ m thickness and spiked with 50 nmol/g of SCH-23390. Ten extractions were per-
formed at random points across the tissue with mean signal intensity used to compare the diferences between 
the sections.
Efects of internal standard. he efect of spraying a non-deuterated internal standard and a deuterated internal 
standard (IS) over the tissue to normalize diferences in ionization response across diferent tissue areas was 
explored. A mimetic liver tissue calibration curve was constructed containing clozapine, albendazole, tamoxifen 
and astemizole (in cassette) at the following concentration levels 0, 0.1, 0.5, 1, 5, 10, 20, 50 and 100 nmol/g. A 
compound taken from the AstraZeneca compound collection that is routinely used as an internal standard in 
LC-MS/MS analysis was used as an non-deuterated IS (an acidic quinoline tetrazole, LogD 2.67, RMM 407.5), 
clozapine-d4 was used as a deuterated IS. he internal standard was sprayed over the tissue sections using a 
TMsprayer (HTx Technologies, Chapel Hill, North Carolina, USA). An additional experiment was performed 
with the clozapine-d4 spiked at 1 uM in the LESA extraction solvent. Ten LESA extractions were performed at 
random points across each calibration standard and the signal intensity was used to calculated a mean value and 
coeicient of variation for each calibration point in the presence and absence of the internal standard.
Optimized LESA quantitative mass spectrometry imaging. LESA MSI was performed using 
LESA-MS/MS on a Triversa Nanomate chip based electrospray ionization system (Advion, Ithaca, NY, USA) 
coupled to a QTRAP 5500 (AB Sciex, Framingham, MA, USA) mass spectrometer operated in positive ion MRM 
mode. he LESA sampling method consisted of aspiration of a 0.9 µ L volume of extraction solution (Acetonitrile/
water/Formic Acid 60/40/0.1 v/v/v). 0.5 µ L of the solution was then dispensed at a height of 0.4 mm above the 
tissue with a 3 s post dispense delay time, a liquid micro junction between the pipette tip and the sample was 
maintained throughout the procedure. 1.1 µ L of sample was re-aspirated into the pipette tip prior to infusion via 
the nanomate chip for MS/MS analysis. Relative abundance was determined between samples by comparison 
of MRM transition intensity at m/z 326.9 > 269.8, 266.1 > 234.3, 372.0 > 71.9 and 459.1 > 218.0 for clozapine, 
albendazole, tamoxifen and astemizole and 472.3 > 436.2, 313.1 > 256.1, 402.2 > 358.1 and 394.2 > 278.0 for ter-
fenadine, olanzapine, moxiloxacin and erlotinib respectively. LESA-MS/MS data was processed using a purpose 
built sotware package capable of extracting relative abundance values from Analyst 6.1 (ABSciex, Framingham, 
MA, USA).
LESA-MS/MS images were created using in-house developed sotware capable of colour grading ion inten-
sities acquired from each individual LESA spot in a heat map coniguration ixing the colour scale at maximum 
for the highest intensity response in the spot and scaling the colour intensity down accordingly relative to the 
maximum.
Analysis of liver homogenates by LC-MS/MS. Experimental procedures for the preparation of liver 
homogenates, calibration standards and quality controls and general LC-MS/MS methodologies can be found in 
the supplementary information.
DesI mass spectrometry imaging. DESI MSI analysis was performed using a Q-Exactive mass spectrom-
eter (hermo Fisher Scientiic Inc., Bremen, Germany) operated in positive ion mode. he mass spectrometer 
was equipped with an automated Prosolia 2D DESI source (Indianapolis, IN, USA). Mass spectra were collected 
in the mass range of m/z 200–600 at a mass resolution of 140,000 (at m/z 200). Methanol/water (95:5 v/v) was 
used as the electrospray solvent held at 4.5 kV spray voltage and delivered at a low-rate of 1.5 µ L/min by a Dionex 
Ultimate 3000 nanoLC pump (hermo Fisher Scientiic). Nitrogen was used as nebulising gas at a pressure of 7 
bars. he height distance between the DESI sprayer and the sample surface was set to 1.5 mm with the distance 
between the sprayer and the inlet capillary set to 7 mm. he distance between the sample surface and the inlet 
capillary of the mass spectrometer was < 1 mm. he angle between the sprayer tip and the sample surface was 
set at 750°. Spatial resolution for the imaging experiment was set to 125 µ m with 173.61 µ m/s scan speed at an 
injection time of 150 ms per spectrum. Individual horizontal line scans were combined into imzML format using 
the imzML converter V.1.1.4.5 (www.maldi-msi.org). Data visualization and region of interest extraction was 
performed using MSiReader v0.0523. Intensity data was extracted for each pixel within a region of interest and 
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Figure 1. (a) LESA-MSI images of olanzapine, moxiloxacin, terfenadine and erlotinib in mimetic liver 
calibration standards showing the increasing intensity throughout the calibration range. Heme and a generic 
lipid marker are included to show the contrast between a spiked and endogenous response (b) LESA-MSI 
images of dosed rat liver tissue sections showing the distribution of olanazapine, moxiloxacin, terfenadine and 
erlotinib at 2 and 6 h post dose.
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subsequently averaged using Microsot Excel. All images were created using 0.01 Da bin size and linear interpo-
lation (order 1).
Results and Discussion
Prior to any quantitative LESA analysis a study was undertaken to optimize the method used in previously 
reported work from our laboratory11. he optimization experiments consisted of comparison of diferent extrac-
tion solvent systems, the efects of diferent tissue section thickness, the length of time the extraction solvent 
is in contact with the tissue (solvent dwell time) and the efects of using an internal standard on the analytical 
performance.
LESA Optimization. he solvent systems tested gave varying results. Isopropyl alcohol (SI Fig. 1a) and 
methanol (SI Fig. 1b) based systems gave fairly low signal intensities across all of the diferent solvent composi-
tions with isopropyl alcohol mixed at 60% IPA and methanol mixed at 70% MeOH giving the best results for all 
of the compounds tested. 70% MeOH gave signal intensities roughly 1.5-fold higher than those observed at 60% 
IPA. Extractions that used 70 and 80% IPA resulted in unreliable extractions 6 out of 10 times (60%), this was 
due to loss of the liquid junction between the tissue and the pipette tip caused by the low surface tension in high 
organic content solvent systems. A greater number (8/10) of extractions failed at 80% MeOH, although at all other 
composition ratios the number of failed extractions was less than 2/10.
Acetonitrile based solvents systems (SI Fig. 1c) gave results with higher signal intensities. Extraction failure 
rates at 70 and 80% ACN were 5/10 and 6/10 respectively. Failure rates at 50 and 60% ACN were zero with 60% 
ACN giving the highest mean signal intensity across all of the compounds and solvent compositions tested com-
bined with a consistently good extraction. hus, 60% ACN with 0.1% formic acid was used as a standard extrac-
tion system in all subsequent experiments.
Liver mimetic tissue sections cut at 12, 25 and 50 µ m thickness were analyzed. he efect on signal intensity 
was negligible across the diferent tissue thicknesess and for each of the four compounds analyzed (SI Fig. 2). 
Extraction failure across each of the diferent sections was 3/10. It was decided to use 12 µ m tissue thickness for 
any subsequent analysis as this is the standard used for MALDI and DESI analysis within our laboratories.
Diferent solvent dwell times (time solvent/tissue liquid junction is maintained) were evaluated. his showed 
a gradual increase for the analyte SCH-23390 when moving from 1 s to 3 s dwell time (SI Fig. 3) but the signal 
intensity subsequently dropped moving from the 3 s dwell time to 4 s and 5 s dwell time. Extraction failure was 
Figure 2. (a) Calibration curves of Olanzapine, moxiloxacin, terfenadine and erlotinib in rat liver mimetic 
tissue standards analyzed by LESA-MSI. (b) Back calculated concentrations of each calibration standard used in 
the construction of the calibration lines with corresponding accuracy values in parenthesis.
Timepoint (h)
Cassette 2 h Cassette 6 h Discrete 2 h Discrete 6 h
Compound LESA Homog. DESI LESA Homog. DESI LESA Homog. DESI LESA Homog. DESI
Olanzapine 9.3 10.2 14.4 12.5 18.6 19.6 25.8 19.6 38.1 8.3 10.0 6.2
Moxiloxacin 15.6 14.6 10.8 12.0 12.5 16.4 — — — — — —
Erlotinib 38.4 28.5 26.9 26.6 25.2 19.8 — — — — — —
Terfenadine 11.9 9.0 12.0 4.0 4.7 2.8 — — — — — —
Table 1.  Comparison of back calculated concentrations (nmol/g) for compounds analyzed by LESA-MSI, 
homoginization and DESI-MSI.
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≤ 1/10 across all of the dwell times in the experiment. Increasing variability with increasing dwell time resulted 
from the instability of the liquid junction over time for some extractions. A dwell time of 3 s was used as standard 
for all subsequent experiments.
Efects of using an Internal Standard. he efects of using an internal standard to normalize diferent 
ionization suppression efects across tissue has been widely reported in MALDI imaging24,25. Here the most com-
monly used approaches were reproduced using LESA-MSI and experiments were conducted in the presence of 
a non-deuterated IS (standard AZ internal standard used for plasma analysis) and deuterated IS (clozapine-d4), 
both applied over the tissue at a constant concentration. A further experiment explored the use of the deuterated 
internal standard spiked into the LESA extraction solution.
When a non-deuterated IS was used the co-eicient of variation across all of the compounds at each calibra-
tion point ranged between 19.5–42.5% compared to 8.6–41.8% when no IS was used indicting greater variability 
when the IS was present. he diferences were even more apparent when each calibration level and each com-
pound was compared directly (SI Table 1) with the IS showing a greater co-eicient of variation at all points (with 
the exception of Albendazole 5 nmol/g level, 26.8% no IS vs. 24.4% with IS).
The experiment was repeated using clozapine-d4 as the IS. This had a similar result showing a clozap-
ine co-eicient of variation range of 19.3–44.0% in the absence of IS and 17.1–64.1% in the presence of the 
clozapine-d4 IS. When each individual calibration point is compared (SI Table 2) the variation in the presence 
of the clozapine-d4 is more variable at all of the calibration points with the exception of the 5 nmol/g standard, 
indicating the deuterated standard made the variation worse.
As an alternative to spraying the IS over the tissue sections, spiking the IS into the LESA extraction solvent 
was attempted. his experiment resulted in a co-eicient of variation range of 12.8–46.3 with no IS compared 
to 13.0–41.1% in the presence of clozapine-d4 (SI Table 3). When individual points were compared the data 
with the clozapine-d4 spiked into the extraction solvent was less variable at all of the points except the 0.1 and 
0.5 nmol/g calibration standards which gave 12.6% no IS vs. 19.7% with IS and 40.3% no IS vs. 41.1% with IS. his 
result would indicate that the presence of the deuterated internal standard decreases the variation observed in 
the experiment and we would recommend using this approach where a deuterated internal standard is available. 
Deuterated standards are not usually available in the early discovery phase of pharmaceutical development and 
as we intended to develop a widely applicable approach it was decided to progress the quantitation experiments 
without an internal standard.
Quantitative LESA experiments. he objective of this study was to establish a robust and reproduci-
ble method for quantitative LESA-MSI analysis. he mimetic tissue model lends itself well to LESA-MSI anal-
ysis, ofering a large enough sample area to accommodate the lower spatial resolution of the LESA technique, 
something that cannot easily be achieved using conventional standard spotting techniques used in higher spatial 
Figure 3. DESI-MSI images of olanzapine, moxiloxacin, erlotinib and terfenadine in rat liver mimetic 
calibration standards and rat liver ‘unknown’ samples. Poor detection of moxiloxacin, manifested in the 
compound being detected in all samples and highlighting the halo efect around the top liver mimetic tissue 
section.
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resolution MALDI analysis. he mimetic tissue model utilizes un-diluted homogenized tissue in the preparation 
of the mimetics, presenting a control matrix for spiked standards. Here we report data to support the use of 
mimetic tissues for quantitative LESA-MSI and compare and contrast the results to data generated by classical 
tissue homogenization and analysis by LC-MS/MS and to quantitative DESI-MSI.
Quantitation of dosed rat tissues. Quantitation of olanzapine, moxiloxacin, erlotinib and terfenadine 
was performed on liver sections were animals had been cassette dosed at 10, 25, 10, 25 mg/kg of the compounds 
respectively. Liver samples were collected from rats at 2 and 6 h post dose. 2 and 6 h liver sections from rats dosed 
discretely with olanzapine at 10 mg/kg were also tested. Residual liver tissue was sent for homogenization analysis 
by LC-MS/MS. Images of the mimetic liver calibration standard sections and dosed liver sections are presented in 
Fig. 1. he analytes were distributed continuously but at a range of abundances throughout the liver mimetics and 
the dosed samples. Tissue homogeneity was visually assessed via microscope ater sectioning.
he calibration curves derived from the mimetic liver calibration standards are summarized in Fig. 2a. he 
linearity of the response for all four analytes was acceptable with R2 values equal to 0.9933, 0.9998, 0.9994 and 
0.9996 for olanzapine, moxiloxacin, erlotinib and terfenadine respectively. Back calculated concentrations for all 
of the calibration standards used to construct the calibration curves are reported in Fig. 2b. Accuracy of the cali-
bration standards for each compound ranged between 79.3–133.5%, 88.4–118.2%, 80.9–114.8% and 78.3–109.6% 
for olanzapine, moxiloxacin, erlotinib and terfenadine respectively. he LESA extraction failure rate (measured 
by monitoring nanospray ion current) for the experiment was ≤ 5%. Failed extractions were repeated at the end 
of the analytical run to complete the data set.
Comparison with homogenate LC-MS/MS data. Mean intensity of each analyte in each section was 
calculated from all of the sampling points across the entire tissue area. his mean intensity was used to back calcu-
late the concentration in the unknown samples from the mimetic calibration curves, giving a mean concentration 
across the entire tissue of interest. his value provided a direct comparison to the concentration data generated 
by LC-MS/MS analysis (Table 1). he concentrations observed in the unknown samples for each analyte were 
within the calibration range used and the correlation between the concentration data derived from LESA-MSI 
and LC-MS/MS was similar for each of the analytes. he percentage diference between the LESA and the LC-MS/
MS results for olanzapine, moxiloxacin, erlotinib and terfenadine ranged from 9.1–32.8, 3.8–7.0, 5.6–35.1 and 
14.0–32.3% respectively across the diferent time points and dosing regimens.
Comparison with DesI-MsI data. LESA-MSI and DESI-MSI are both spray based analytical techniques 
and as such should show similar results. DESI-MSI is being increasingly used within academia and industry as 
a reliable and robust imaging technique26. Quantitative DESI-MSI has still to be extensively compared to other 
techniques such as LC-MS/MS and MALDI-MSI but several groups have reported positive quantitative meas-
urements22. Adjacent sections to those run by LESA-MSI were used to repeat the analysis using DESI-MSI anal-
ysis (Fig. 3). DESI-MSI was sensitive across the calibration range used, giving a limit of quantitation (LOQ) of 
1.0 nmol/g for olanzapine, erlotinib and terfenadine and 4.98 nmol/g for moxiloxacin. his compared to a LOQ 
of 0.5 nmol/g for all analytes by LESA-MSI analysis. To our knowledge this is the irst time a comparison between 
the two techniques has been performed, the diferences however could be caused by the use of diferent mass ana-
lyzers. DESI-MSI also operates at higher spatial resolution than LESA-MSI so could be inherently more sensitive 
when compared directly.
Figure 4. Calibration curves of Olanzapine, moxiloxacin, terfenadine and erlotinib in rat liver mimetic 
tissue standards analyzed by DESI-MSI. (b) Back calculated concentrations of each calibration standard used 
in the construction of the calibration lines with corresponding accuracy values in parenthesis.
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he calibration curves derived from the DESI-MSI analysis of the mimetic liver calibration standards are 
summarized in Fig. 4a. he linearity of the response for all four analytes was good with R2 values equal to 0.9999, 
0.9998, 0.9997 and 1.0000 for olanzapine, moxiloxacin, erlotinib and terfenadine respectively. Back calculated 
concentrations for all of the calibration standards used to construct the calibration curves are reported in Fig. 4b. 
Accuracy of the calibration standards for each compound was 82.8–136.5%, 81.4–110.2%, 81.3–105.9% and 
80.8–131.0% for olanzapine, moxiloxacin, erlotinib and terfenadine respectively. Moxiloxacin sensitivity was 
relatively low compared to the other analytes, this can be clearly observed in Fig. 4a by the low intensity calibra-
tion curve for the compound. Sensitivity for each compound was variable between LESA-MSI and DESI-MSI 
with erlotinib giving the highest sensitivity in LESA-MSI but terfenadine being more sensitive in DESI-MSI. his 
could be due to extraction eiciency of the diferent compounds in the diferent extraction solvent systems being 
used in the two techniques.
he concentrations observed in the dosed samples for each analyte were within the calibration range used 
(Table 1). he correlation between the concentration data derived from LESA-MSI and DESI-MSI was compara-
ble for each of the analytes. he percentage diference (using DESI-MSI as the standard) between the LESA and 
the DESI-MSI results for olanzapine, moxiloxacin, erlotinib and terfenadine ranged from 33.8–36.2, 26.8–44.4, 
34.3–42.7 and 0.8–42.8% respectively across the diferent time points and dosing regimens.
DESI-MSI also correlated well with the LC-MS/MS results giving a percentage diference (using the LC-MS/
MS data as standard) of 5.4–41.2%, 26.0–31.2%, 5.6–21.4% and 33.3–40.4% for olanzapine, moxiloxacin, erlo-
tinib and terfenadine respectively.
hese results were thought to be a reasonable diference when quantifying drugs in tissues using diferent 
analytical techniques.
Conclusion
Liquid extraction surface analysis has been demonstrated to be a reliable low resolution mass spectrometry imag-
ing technique to qualitatively image compound distribution in tissue sections. Qualitative images highlight the 
distribution of drugs in tissue, but oten images can be misleading due to the scaling methods and any thresh-
olding used in the visualization of the images27. Quantitative measurements give a deinitive answer as to the 
drug concentration within a particular tissue. LESA-MSI has many advantages over traditional homogeniza-
tion analysis such as speed of analysis, increased sample stability, low sample use allowing further analysis by 
other techniques and arguably the largest beneit, spatial resolution. If compound levels are located in a speciic 
sub-compartment of an organ this information is lost with homogenization and the concentration is diluted as an 
average of all of the tissue sampled. Here we have shown that a mimetic tissue model lends itself well to quantita-
tive LESA-MSI, having many advantages over more traditional quantitative mass spectrometry imaging methods. 
Indeed, mimetics were used as a basis for LESA method optimization in the work presented here, providing some 
fundamental changes that improved the sensitivity, reproducibility and robustness of the technique and ulti-
mately a better platform on which to perform quantitative LESA analysis. he mimetic tissue can be used to make 
reasonably large tissue sections which makes it ideal for lower resolution imaging platforms such as LESA-MSI.
he tissue mimetic model however is not without its drawbacks. It is labor intensive when compared to simpler 
standard spotting techniques, uses quite high quantities of control tissue and its application to more structurally 
diverse tissue types such as brain has not yet been demonstrated.
LESA-MSI is oten employed when other MSI techniques have failed to detect analytes of interest, due to the 
techniques greater sensitivity resulting from the larger sampling area. It can also be used when proiling, rather 
than imaging, drug distribution in large tissues from higher animals (e.g. dog liver). Typically in pharmaceutical 
R&D the diferent MSI platforms (LESA, MALDI, DESI-MSI) are used in combination, complementing data from 
standard bioanalysis with information from other multimodal analysis.
Quantitative LESA-MSI is not limited to detection of drugs in tissues, work is ongoing to expand the use of the 
mimetic model to quantitation of endogenous small molecules and small peptides as markers for drug induced 
eicacy in our projects using stable labelled standards.
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